Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Infectious Diseases

Volumn 47, Issue 11, 2015, Pages 789-795

  Kernéis, Solen ^a,b,d   Valade, Sandrine ^a   Geri, Guillaume ^a,b   Compain, Fabrice ^a,b,c   Lavollay, Marie ^a,b,c   Rostane, Hidayeth ^a   Carbonnelle, Etienne ^a,b,c   Mainardi, Jean Luc ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d Institut Cochin   (France)

Author keywords

Cefoxitin; Enterobacteriaceae; Extended spectrum beta lactamase

Indexed keywords

CEFOXITIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL PRACTICE; CYSTITIS; DRUG EFFICACY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; NEPHRITIS; NONHUMAN; OBSERVATIONAL STUDY; PROSTATITIS; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEFOXITIN; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962480860     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1062133     Document Type: Article

References (18)

1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al Diagnosis and management of complicated intra-Abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis 2010; 50: 133-64.
2. Jacoby G A, Carreras I.Activities of beta-lactam antibiotics against Escherichia coli strains producing extendedspectrum beta-lactamases Antimicrob Agents Chemother 1990; 34: 858-62.
3. Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, et al Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase Antimicrob Agents Chemother 2012; 56: 1376-81.
4. Pangon B, Bizet C, Buré A, Pichon F, Philippon A, Regnier B, et al In vivo selection of a cephamycinresistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase J Infect Dis 1989; 159: 1005-6.
5. Boyer M, Bignon A, Dessein R, Faure K, Guery B, Kipnis E.[Cefoxitin and ESBL.] Med Mal Infect 2012; 42: 126-8 (in French).
6. P ilmis B, Parize P, Zahar J R, Lortholary O.Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae Eur J Clin Microbiol Infect Dis 2014; 33: 1263-5.
7. Park S H, Choi S M, Chang Y K, Lee D G, Cho S Y, Lee H J, et al The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli J Antimicrob Chemother 2014; 69: 2848-56.
8. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, 2014 Available from: http://www.eucast.org/
9. Comité de l'Antibiogramme de la Société Fran ça ise de Microbiologie Recommandations 2015 Available from: http://www.sfm-microbiologie.org/
10. Nordmann P, Poirel L.The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide Clin Microbiol Infect 2014; 20: 821-30.
11. Lee N Y, Lee C C, Huang W H, Tsui K C, Hsueh P R, Ko WC Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum betalactamase-producing Enterobacteriaceae: MIC matters Clin Infect Dis 2013; 56: 488-95.
12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME Carbapenems versus alternative antibiotics for the treat-ment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-Analysis J Antimicrob Chemother 2012; 67: 2793-803.
13. Serres A, Gibold L, Dalmasso G, Robin F, Bonnet R, Delmas J.Evaluation of the efficiency of cefoxitin/cefepime combination against Enterobacteriaceae resistant to expanded-spectrum cephalosporins Int J Antimicrob Agents 2015; 45: 86-7.
14. Jacoby GA AmpC beta-lactamases Clin Microbiol Rev 2009; 22: 161-82.
15. Palasubramaniam S, Muniandy S, Navaratnam P.Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia J Microbiol Immunol Infect 2009; 42: 129-33.
16. Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, et al Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli Antimicrob Agents Chemother 2014; 58: 4899-4901.
17. Kosmidis J, Hamilton-Miller J M, Gilchrist J N, Kerry D W, Brumfitt W.Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin Br Med J 1973; 4: 653-5.
18. Société de Pathologie Infectieuse de Langue Franç aise Infections urinaires-Recommandations 2014 Available from: http://www.infectiologie.com/